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Abstract
Background: Many studies have already reported encouraging results in the prophylactic therapy
of migraine by acupuncture, but there seems to be a lack of high quality randomized controlled
trials from China. We design and perform a randomized controlled clinical trial to evaluate the
efficacy of acupuncture compared with flunarizine in the prophylactic therapy of patients with
migraine without aura in China.
Methods: This trial is a multicenter, prospective, randomized controlled clinical trial. The 140
migraine patients are randomly allocated to two different groups. The acupuncture groups (n = 70)
is treated with acupuncture and placebo medicine; while the control group (n = 70) is treated with
sham acupuncture and medicine (Flunarizine). Both Flunarizine and placebo are taken 10 mg once
per night for the first 2 weeks and then 5 mg once per night for the next 2 weeks. Patients in both
groups receive 12 sessions of verum/sham acupuncture in 4 weeks.
Discussion: The study design and the long term clinical practice of acupuncturists guarantee a high
external validity for the results. The results of our trial will be helpful to supply the evidence on the
efficacy of acupuncture for migraine prophylaxis in China.
Trial Registration: The trial is registered at Controlled Clinical Trials: ISRCTN49839714.
Background
Migraine leads to recurrent attacks of mostly unilateral,
pulsating headache with associated symptoms such as
photophobia, phonophobia, nausea, and vomiting. The
diagnosis of migraine is based on criteria developed by
the International Headache Society in 1988 and revised in
2004 – the International Classification of Headache Dis-
orders II (ICHD II) [1]. Migraine prevalence are roughly
12% of the adults in western countries [2] and 4.2%–
14.6% in China [3]. Epidemiological studies from several
countries showed that the prevalence of migraine was 16–
18% in women and 6–8% in men [4,5]. Approximately
90% of the migraine patients have moderate or severe
pain, three quarters have a reduced ability to function dur-
ing the headache attacks, and one-third require bed rest
during their attacks [6].
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Some patients with migraine are able to identify headache
triggers. Triggers may be inconsistent or additive and are
not specific to migraine. For example, menses is a trigger
for 60% of female migraine patients. Stress or "let-down"
after a stressful event, change in meal schedules or insom-
nia, and such environmental factors as loud noise, odors,
or flickering lights may also precipitate migraine head-
ache [7].
Migraine headache has a complex pathophysiology. Both
vascular and neuronal mechanisms have been proposed.
Although the mechanisms haven't been exactly known
yet, several medications have been given to alleviate pain
of patients. Pharmacotherapy can be abortive or prophy-
lactic, and patients who experience frequent, severe head-
aches often require both approaches. Abortive
medications used more than 2 days a week on a regular
basis may lead to chronic daily or rebound headaches, so
patients with headaches symptoms more than a few days
a week should be on headache prophylactic therapy [7].
The goals of migraine prophylactic therapy are to (1)
reduce attack frequency, severity, and duration, (2)
improve responsiveness to treatment of acute attacks, and
(3) improve function and reduce disability. Additional
goals are to reduce costs and possibly prevent progression
of episodic to chronic migraine. Prophylactic medication
groups include β-adrenergic blockers, antidepressants,
calcium-channel antagonists, serotonin antagonists, anti-
convulsants, nonsteroidal anti-inflammatory drugs, and
others (vitamins, minerals, natural products) [8]. Cal-
cium-channel antagonists such as flunarizine have been
used commonly in China. Choice is based on efficacy,
adverse events, and coexistent conditions. However, most
of medications have side effects and contraindication that
may limit their use.
Acupuncture, which is one of the main treatment modal-
ities of Traditional Chinese Medicine (TCM), has been
used for both the prevention and treatment of diseases for
over three thousand years [9]. Although how acupuncture
works is still unknown [10], the range of indications of
acupuncture (especially for pain management), the vari-
ety of different acupuncture methods and the probability
that the effects are made up of a specific and a nonspecific
component have been acknowledged by more and more
western countries [11].
Many studies have already reported encouraging results in
the therapy of migraine by acupuncture. In 2001 a system-
atic review on acupuncture for idiopathic headache had
underlined the existing evidence that acupuncture had an
effective role in the treatment of patients with migraine
[12], but methodological or reporting shortcomings were
found in the majority of the studies, so the evidence was
insufficient to determine the efficacy of acupuncture com-
pared to medication, or to wait list control or sham acu-
puncture, in the management of patients with migraine.
Since that systematic review, several large, randomized tri-
als on the effectiveness of acupuncture as treatment for
migraine prophylaxis have been published in western
countries, but there seems to be a lack of high quality ran-
domized controlled trials from China. China is the origin
of acupuncture and the country where acupuncture has
been used most commonly in clinical practice. Therefore,
we are performing a randomized controlled trial to inves-
tigate the efficacy of acupuncture compared with flunar-
izine in patients who have frequent migraine attacks in
China.
Methods
This trial is a multicenter prospective, randomized, con-
trolled clinical trial. The central randomization is per-
formed by Research Center of Clinical Epidemiology
Affiliated to Peking University in China, which uses block
randomization to generate the random allocation
sequence and prepares a predetermined computer-made
randomization opaque sealed envelopes. The opaque
sealed envelopes are numbered consecutively and were
connected into a strain. It is requested that each envelope
should be separated from the strain and then be opened
in sequence only after baseline period when the patient
has been registered in the trial. Patient and assessors are
blinded (blinded telephone interviewers) with regard to
the acupuncture treatment administered. The trial is exe-
cuted in the following five hospitals from June 2007 to
June 2009: Beijing Traditional Chinese Medicine Hospital
Affiliated to Capital Medical University, Peking University
Third Hospital, Beijing Tiantan Hospital Affiliated to Cap-
ital Medical University, Huguosi Hospital Affiliated to the
Beijing University of Chinese Medicine and Dongzhimen
Hospital Affiliated to the Beijing University of Chinese
Medicine. Physicians who enroll participants and asses-
sors who collect data in these five hospitals must have a 3-
day training seminar concerning treatment modalities
and trial's documentation prior to the trial to make sure
all practices at each of the five hospitals were the same.
Periodic check-up contained the coincidence of the prac-
tices taken in every hospital.
This trial is performed according to the principles of the
Declaration of Helsinki (Version Edinburgh 2000). The
trial protocol has been approved by the Research Ethical
Committee of Beijing Traditional Chinese Medicine Hos-
pital Affiliated to Capital Medical University on May
2007.
Participants
One hundred and forty patients with migraine without
aura enrolled in the trial are recruited from outpatient in
acupuncture clinics of the five hospitals. The main inclu-Trials 2009, 10:25 http://www.trialsjournal.com/content/10/1/25
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sion criteria are: patients suffering from migraine without
aura (more than 2 migraine attacks in 4 weeks), diagnosed
according to diagnostic criteria of the International Head-
ache Society [1]; male or female; aged 18–65 years;
patients who had not used acupuncture or drugs with
migraine prophylactic effects within the last 3 months;
patients who have given written informed consent.
The main exclusion criteria are: tension-type headache,
cluster headache and other primary headaches; secondary
headache and other neurological diseases; neuralgia of
the face or head; pregnancy, nursing mother or insuffi-
cient contraception; use of prophylactic migraine medica-
tion in the last 3 months; therapy with β-blocker in the
last 3 months; intake of antipsychotic or antidepressant
drugs; participation in another clinical trial; having family
history of depression, Parkinson disease and other extra-
pyramidal diseases.
According to the previous studies in China and our pilot
study, we anticipate that the proportion of responders
[13] (50% or greater reduction in attack frequency) would
be 65% [14,15] in control group and 90% [16] in acu-
puncture group. Based on 0.9 power to detect a significant
difference (α = 0.05, two-sided), 56 patients are required
for each group calculated by EpiCalc 2000 Version 1.02.
To compensate for dropout patients, we plan to enroll 70
patients per group.
Procedures
According to predetermined randomization envelopes,
140 eligible patients are randomly allocated to acupunc-
ture group or control group (see Figure 1). The patients
have an equal probability of being assigned to either of
two groups. Patients need to record headaches and usage
of acute medication in headache diary from baseline
period to the 16th week after randomization. According to
Case Report Form including all outcome measures, end-
points are collected separately 16 weeks after randomiza-
tion by blinded telephone interviewers in the five
hospitals to evaluate the long term effect of acupuncture
prophylaxis.
Intervention
In addition to rigorous methodological quality, both
verum acupuncture and sham acupuncture interventions
have been proposed based on a broad literature review
and a consensus with acupuncture experts in Beijing Tra-
ditional Chinese Medicine Hospital. We conducted a pilot
study with sample size 32 per group to confirm the effi-
cacy of verum acupuncture compared with sham acu-
puncture. Besides, the interventions of two groups are
based on the experiences of physicians who had worked
with acupuncture for 20 years.
In the acupuncture group, 3 acupuncture sessions per
week are carried out and placebo medicine is taken once a
night for 4 weeks. In the control group, medicine (flunar-
izine) once a night for 4 weeks is given and 3 sham-acu-
puncture sessions are given per week. There are several
common approaches of verum/sham acupuncture in both
groups including: bilateral points; usage of disposable,
sterile steel needles (0.32 mm × 40 mm); 10–12 needles
used each time; skin disinfection with 75% alcohol; nee-
dles retention for 30 minutes and no moxibustion or elec-
trical stimulation. Patients of both groups received 12
sessions of verum/sham acupuncture in 4 weeks.
The placebo medicines have exactly the same appearance
as true medicines (flunarizine). Both Flunarizine and pla-
cebo are taken 10 mg once per night for the first 2 weeks
and then 5 mg once per night for the next 2 weeks. All
patients are allowed to treat acute headaches as need, but
the type and dose of acute medications should be
recorded in a headache diary.
Verum Acupuncture
The obligatory points used in acupuncture group include
DU20 (Baihui), DU24 (Shenting), GB13 (Benshen), GB8
(Shuaigu), SJ20 (Jiaosun) and GB20 (Fengchi). Addi-
tional points can be chosen according to syndrome differ-
entiation of meridians (see Figure 2):
1. Shaoyang headache (TE-GB): SJ5 (Waiguan), GB34
(Yanglingquan).
2. Yangming headache (LI-ST): LI 4 (Hegu), ST 44 (Neit-
ing).
Trial profile Figure 1
Trial profile.Trials 2009, 10:25 http://www.trialsjournal.com/content/10/1/25
Page 4 of 7
(page number not for citation purposes)
Syndrome differentiation of meridians in headache region Figure 2
Syndrome differentiation of meridians in headache region.Trials 2009, 10:25 http://www.trialsjournal.com/content/10/1/25
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3. Taiyang headache (SI-BL): BL 60 (Kunlun), SI 3
(Houxi).
4. Jueyin headache (PC-LR): LR3 (Taichong), GB40
(Qiuxu).
5. Nausea and vomiting: PC6 (Neiguan).
6. Dysphoria and susceptibility to rage: LR3 (Taichong).
Needles are inserted 10–15 mm in depth and manually
manipulated by rotation methods to produce a character-
istic sensation known as "De Qi".
Sham Acupuncture
To make the quantity of stimulus uniform between two
groups, the decision is made to use the same kind, size
and number of needles for sham acupuncture as which are
used in verum acupuncture. However, the sham points
selected would be confirmed as the distant non-meridian
points that are defined as 3 mm apart from the points
without effects on headache. The procedure for develop-
ing the sham acupuncture protocol contains three steps:
1. Literature search: Based on the search and analyses of
26 Chinese acupuncture ancient articles, 3 Chinese acu-
puncture textbooks and more than one hundred acupunc-
ture modern articles, the points with no reference to
effects on headaches have been enumerated.
2. Point selection: To avoid the effects on headaches and
the effects of alleviating pain, the points in the head,
trunk, hands and feet are excluded. And then 30 points
without effects on headaches are extracted and the loca-
tions 3 mm apart from these points are defined as sham
points, which are used in the control group.
3. Sham points subgroup: 30 sham points are randomly
assigned to five subgroups of control groups which are
labeled from B to F and recorded in the predetermined
computer-made randomization sealed envelope. Each
subgroup has two points on arms and three points on
legs. The patient who belongs to the control group will be
assigned to one of subgroups and the five points in this
subgroup will be used on this patient in the whole treat-
ment period. The details of the sham points in the control
group are in Table 1.
Outcome measures
The efficacy of acupuncture for migraine prophylaxis is
assessed by the following primary outcome measures:
1. Change in frequency and duration of migraine attacks
[13].
2. The proportion of responders, defined as the propor-
tion of patients with a reduction of migraine days by at
least 50% [13].
3. Visual Analogue Scale (VAS) to assess the severity of
migraine pain [17].
4. Short-Form of McGill Pain Questionnaire (SF-MPQ)
[17,18].
The secondary outcome measures include:
1. The summary scales of the SF-36 [19,20].
2. Intake of acute-medication [13].
3. Number of patients with adverse side effects [21].
4. Change in the frequency of nausea and vomiting [22].
The outcome measures above will be assessed before the
treatment, the week of the last acupuncture session and 12
weeks after the last acupuncture session.
Statistical analysis
All analyses will be done on the intention-to-treat group
of participants who have been randomized regardless of
whether they receive any treatment. Missing data will be
replaced according to the principle of the last observation
carried forward. A variance analysis reject the global
hypothesis H0: "There is no difference in the success prob-
ability between two groups." The significant level used for
the statistical analysis is 5%, therefore P < 0.05 indicates
significance. Analysis of variance (ANOVA) for repeated
measures is used to compare the two groups. Compari-
sons within groups for the outcomes in each one of the
time point were done using the Tukey's post hoc test of
Multivariate Analysis of Variance (MANOVA). In the case
of proportions, a chi-square test is applied. Stratified anal-
ysis within five different centers will be performed to con-
trol confounding factor if necessary. All analyses are
performed using the Statistical Package for the Social Sci-
Table 1: The sham points in the control group.
Subgroup Code Arm Leg
1 B LI15† LI14‡ KI9† GB33† LR7†
2 C SJ6‡ SJ8† SP7† KI10† GB38†
3 D LI13‡ PC5‡ GB35† GB37† GB39†
4 E LU5‡ PC2‡ SP9† KI7† LR6†
5 F LI12‡ HT4‡ ST32‡ ST38‡ ST39‡
† Backward 3 mm from the point; ‡ Outward 3 mm from the point.Trials 2009, 10:25 http://www.trialsjournal.com/content/10/1/25
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ences (SPSS) software program (version 13.0) for Win-
dows XP.
Discussion
The question we put forward in this clinical trial is: "Is
acupuncture prophylaxis as effective as flunarizine for
migraine?" Flunarizine is a drug classified as a calcium
channel blocker, which is commonly used in China for
migraine prophylaxis. A large sample size study consid-
ered that flunarizine is safe and effective for the prophy-
lactic treatment of migraine in China [23]. Therefore, we
compare the efficacy of acupuncture with flunarizine
which is chosen as a standard drug therapy. The strength
of our trial is strictly concealed randomization, the suc-
cessful blinding of the patients, data collection in diaries.
Moreover, in this trial all physicians applying acupuncture
treatments have more than 20 years of clinical experience
of acupuncture.
According to the theory of traditional Chinese medicine,
migraine headaches can be considered as syndromes of
meridians [24]. So the acupuncture intervention is given
based on the concept of syndrome differentiation of
meridians. As an important part of the theory of meridi-
ans, syndrome differentiation of meridians has been per-
formed in clinical practice for thousands of years. The aim
of syndrome differentiation of meridians is to analyze the
involvement of the meridians according to the distribu-
tion and indication of meridians for the purpose of pro-
viding evidence for selecting the needling methods [25].
For example, most migraine patients with headache on
the temporal side, where the distribution of meridians of
foot-Shaoyang, should pertain to Shaoyang headache,
while some migraine patients with headache on the fore-
head should pertain to Yangming headache, because fore-
head is the distribution of meridians of foot-Yangming. In
the case of Shaoyang headache, SJ5 and GB34 can be
added besides obligatory points that have to be needled in
the trial.
The protocol of sham points is developed in our trial
according to international considerations about the meth-
odological problems of sham acupuncture [26]. To avoid
any effects on headache, firstly we searched points with-
out effect on headache from both ancient and modern lit-
erature. This method of selecting sham points can be seen
in Alecrim (2008) [22], but our research must be more
extensive, because we searched many Chinese articles,
particularly ancient books, which have not yet been trans-
lated into English. Secondly, as Linde (2005) [27] did, dis-
tant non-meridian point is used as sham point by
needling 3 mm apart from the points without effect on
headache to further avoid the meridian affects in the con-
trol group. Last but not least, there are 30 points without
effects on headache extracted, but only 5 points will be
used to each patient in control group. Points, which are
chosen and made up as a control subgroup, are deter-
mined by computer-made randomization. This process of
confirming sham points could further eliminate potential
effects on headache.
To mask the patients in our trial, sham acupuncture is
adopted in the control group while placebo medicine is
used in acupuncture group, which is considered to benefit
the homogeneity of potential psychological effects and
improve compliance of patients in China. Alecrim (2008)
[22], Diener (2006) [13] and Linde (2005) [27] reported
that sham acupuncture had similar effects to verum acu-
puncture in reducing migraine headaches and both inter-
ventions were effective. They thought that several
nonspecific factors could explain the high improvement
of the sham group, such as the patient's belief in positive
results of the acupuncture treatment and the frequent
patient's contact with the acupuncturist. Even though in
our trial these factors have been standardized as strictly as
possible and the selection of sham points is different from
previously published trials, we cannot rule out that sham
acupuncture intervention may have some physiological
effects. The nonspecific physiological effects of needling
may include local alteration in circulation and immune
function as well as neurophysiological and neurochemi-
cal responses as reported [28,29]. Moreover, the placebo
effects may be higher in pain sufferers than in patients suf-
fering from other complaints [30] and invasive technical
proceedings may have higher analgesic effects than oral
drugs [31,32]. Our design therefore might prefer the flu-
narizine group.
Acupuncture has been used for alleviating acute/chronic
pain for thousands of years. The efficacy of acupuncture as
abortive therapy for patients with migraine headaches has
been proved by many studies [12]. Some studies sug-
gested that sumatriptan was more effective than acupunc-
ture at relieving headache [33]. Therefore, the purpose of
this trial is not to discuss the efficacy of acupuncture as
painkiller but evaluate the efficacy on preventing migraine
attack. The results of our trial will be helpful to supply the
evidence on the efficacy of acupuncture for migraine
prophylaxis in China.
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